| Business Summary | | Vion
Pharmaceuticals,
Inc.
is
a
biopharmaceutical
company
engaged
in
research,
development
and
commercialization
of
therapeutics
and
technologies
for
the
treatment
of
cancer.
The
Company's
product
portfolio
consists
of
one
drug
delivery
platform
and
two
distinct
small-molecule
anticancer
agents.
TAPET
(Tumor
Amplified
Protein
Expression
Therapy),
the
Company's
drug
delivery
system
using
live
bioengineered,
genetically
altered
Salmonella
bacteria,
is
designed
to
deliver
cancer-fighting
drugs
preferentially
to
solid
tumors.
Triapine
prevents
the
replication
of
tumor
cells
by
blocking
a
critical
step
in
the
synthesis
of
DNA.
Sulfonyl
Hydrazine
Prodrugs
are
potent
alkylating
agents
that
are
being
evaluated
in
preclinical
studies.
The
Company
is
developing
several
products
for
the
treatment
of
cancer.
The
core
product
candidates
are
in
various
development
statuses. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Vion
Pharmaceuticals,
Inc.
is
a
biopharmaceutical
company
principally
devoted
to
the
research
and
development
of
therapeutic
products
for
the
treatment
of
cancer
and
cancer-related
disorders.
For
the
six
months
ended
6/30/01,
total
revenues
fell
22%
to
$325
thousand.
Net
loss
applicable
to
Common
rose
7%
to
$7
million.
Results
reflect
lower
contract
research
grants
received
and
the
absence
of
support
services
fees,
partially
offset
by
higher
interest
income. | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| William Miller, 71 Chairman | -- | -- | Alan Kessman, 53 Pres,
CEO | $545K | -- | Steven Koehler CFO | -- | -- | Thomas Mizelle, 48 VP--Operations
and Sec. | 232K | $63K | Bijan Almassian, Ph.D., 46 VP,
Devel. | 192K | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|